vs
Side-by-side financial comparison of BioNTech SE (BNTX) and F5, Inc. (FFIV). Click either name above to swap in a different company.
BioNTech SE is the larger business by last-quarter revenue ($1.5B vs $811.7M, roughly 1.9× F5, Inc.). F5, Inc. runs the higher net margin — 18.2% vs -1.9%, a 20.1% gap on every dollar of revenue.
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
F5, Inc. is an American technology company specializing in application security, multi-cloud management, online fraud prevention, application delivery networking (ADN), application availability and performance, and network security, access, and authorization.
BNTX vs FFIV — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $811.7M |
| Net Profit | $-28.7M | $148.0M |
| Gross Margin | — | 81.4% |
| Operating Margin | -3.1% | 22.1% |
| Net Margin | -1.9% | 18.2% |
| Revenue YoY | — | 11.0% |
| Net Profit YoY | — | 1.5% |
| EPS (diluted) | — | $2.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $811.7M | ||
| Q4 25 | — | $822.5M | ||
| Q3 25 | $1.5B | $810.1M | ||
| Q2 25 | $260.8M | $780.4M | ||
| Q1 25 | — | $731.1M | ||
| Q4 24 | — | $766.5M | ||
| Q3 24 | $1.2B | $746.7M | ||
| Q2 24 | — | $695.5M |
| Q1 26 | — | $148.0M | ||
| Q4 25 | — | $180.1M | ||
| Q3 25 | $-28.7M | $190.5M | ||
| Q2 25 | $-386.6M | $189.9M | ||
| Q1 25 | — | $145.5M | ||
| Q4 24 | — | $166.4M | ||
| Q3 24 | $198.1M | $165.3M | ||
| Q2 24 | — | $144.1M |
| Q1 26 | — | 81.4% | ||
| Q4 25 | — | 81.5% | ||
| Q3 25 | — | 82.2% | ||
| Q2 25 | — | 81.0% | ||
| Q1 25 | — | 80.7% | ||
| Q4 24 | — | 81.7% | ||
| Q3 24 | — | 80.8% | ||
| Q2 24 | — | 80.4% |
| Q1 26 | — | 22.1% | ||
| Q4 25 | — | 26.0% | ||
| Q3 25 | -3.1% | 25.4% | ||
| Q2 25 | -192.1% | 25.2% | ||
| Q1 25 | — | 21.7% | ||
| Q4 24 | — | 26.8% | ||
| Q3 24 | 0.8% | 25.6% | ||
| Q2 24 | — | 23.4% |
| Q1 26 | — | 18.2% | ||
| Q4 25 | — | 21.9% | ||
| Q3 25 | -1.9% | 23.5% | ||
| Q2 25 | -148.2% | 24.3% | ||
| Q1 25 | — | 19.9% | ||
| Q4 24 | — | 21.7% | ||
| Q3 24 | 15.9% | 22.1% | ||
| Q2 24 | — | 20.7% |
| Q1 26 | — | $2.58 | ||
| Q4 25 | — | $3.10 | ||
| Q3 25 | — | $3.25 | ||
| Q2 25 | — | $3.25 | ||
| Q1 25 | — | $2.48 | ||
| Q4 24 | — | $2.82 | ||
| Q3 24 | — | $2.79 | ||
| Q2 24 | — | $2.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.4B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $3.6B |
| Total Assets | — | $6.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.4B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $935.6M |
| Q1 26 | — | $3.6B | ||
| Q4 25 | — | $3.5B | ||
| Q3 25 | — | $3.6B | ||
| Q2 25 | — | $3.5B | ||
| Q1 25 | — | $3.3B | ||
| Q4 24 | — | $3.2B | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | — | $3.0B |
| Q1 26 | — | $6.5B | ||
| Q4 25 | — | $6.3B | ||
| Q3 25 | — | $6.3B | ||
| Q2 25 | — | $6.1B | ||
| Q1 25 | — | $5.9B | ||
| Q4 24 | — | $5.9B | ||
| Q3 24 | — | $5.6B | ||
| Q2 24 | — | $5.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $525.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $525.1M | ||
| Q4 25 | — | $159.2M | ||
| Q3 25 | — | $208.1M | ||
| Q2 25 | — | $282.2M | ||
| Q1 25 | — | $256.6M | ||
| Q4 24 | — | $202.8M | ||
| Q3 24 | — | $246.5M | ||
| Q2 24 | — | $159.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $149.5M | ||
| Q3 25 | — | $191.9M | ||
| Q2 25 | — | $273.7M | ||
| Q1 25 | — | $246.1M | ||
| Q4 24 | — | $194.7M | ||
| Q3 24 | — | $240.4M | ||
| Q2 24 | — | $153.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 18.2% | ||
| Q3 25 | — | 23.7% | ||
| Q2 25 | — | 35.1% | ||
| Q1 25 | — | 33.7% | ||
| Q4 24 | — | 25.4% | ||
| Q3 24 | — | 32.2% | ||
| Q2 24 | — | 22.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 2.0% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 0.8% |
| Q1 26 | — | 3.55× | ||
| Q4 25 | — | 0.88× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 1.49× | ||
| Q1 25 | — | 1.76× | ||
| Q4 24 | — | 1.22× | ||
| Q3 24 | — | 1.49× | ||
| Q2 24 | — | 1.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
